SCHEMBL3894601

SCHEMBL3894601

CC(OC(=O)N1CCc2ccccc2C1)C(=O)NC(C)(C#N)OCc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABHD6 Q9BV23 1/20 0.45
MMP8 P22894 1/20 0.43
RECQL P46063 1/20 0.42
TMEM97 Q5BJF2 2/20 0.40
SIGMAR1 Q99720 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
TAAR1 Q96RJ0 1/20 0.40
NOTUM Q6P988 1/20 0.40
DPP4 P27487 3/20 0.40
DPP8 Q6V1X1 2/20 0.40
HDAC8 Q9BY41 1/20 0.39
KMT2A Q03164 2/20 0.39
ACE P12821 1/20 0.39
DPP7 Q9UHL4 2/20 0.39
PSMB1 P20618 1/20 0.39
PSMB2 P49721 1/20 0.39
MEN1 O00255 1/20 0.39
HCRTR1 O43613 1/20 0.39
HCRTR2 O43614 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3898451 0.90 ABHD6 (0.42) ABHD6MMP8RECQLTMEM97SIGMAR1
SCHEMBL3909384 0.89 ABHD6 (0.44) ABHD6MMP8RECQLTMEM97SIGMAR1
SCHEMBL3899406 0.88 ABHD6 (0.42) ABHD6MMP8RECQLTMEM97SIGMAR1
SCHEMBL3910427 0.88 ABHD6 (0.45) ABHD6MMP8RECQLTMEM97SIGMAR1
SCHEMBL3895583 0.87 ABHD6 (0.46) ABHD6MMP8RECQLTMEM97SIGMAR1
SCHEMBL3898337 0.86 ABHD6 (0.41) ABHD6MMP8RECQLTMEM97SIGMAR1
SCHEMBL3904024 0.79 MMP8 (0.40) ABHD6MMP8RECQLTMEM97SIGMAR1
SCHEMBL3894604 0.78 CTSS (0.53)
SCHEMBL3897434 0.74 CTSS (0.48) ALDH1A1KMT2AMEN1
SCHEMBL3898080 0.73 MEN1 (0.46) MMP8ALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1399431-B1 NOVEL NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES BOEHRINGER INGELHEIM PHARMA (US) 2009-02-18 EP claimed
US-6982263-B2 Nitriles useful as reversible inhibitors of cysteine proteases BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-01-03 US claimed
US-20030119827-A1 Novel nitriles useful as reversible inhibitors of cysteine proteases BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2003-06-26 US claimed
WO-2002100849-A2 NOVEL NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2002-12-19 WO claimed
EP-1399431-B1 NOVEL NITRILES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES BOEHRINGER INGELHEIM PHARMA (US) 2009-02-18 EP disclosed
US-6982263-B2 Nitriles useful as reversible inhibitors of cysteine proteases BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-01-03 US disclosed
US-20030119827-A1 Novel nitriles useful as reversible inhibitors of cysteine proteases BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2003-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030119827-A1 Novel nitriles useful as reversible inhibitors of cysteine proteases NOS1, CTSK, CTSS ABHD6 4134/4885MMP8 60/4885RECQL 3920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.